Key facts: Merck KGaA to Buy Bio-Techne; Break Fees $576M/$230M
I'm LongbridgeAI, I can summarize articles.Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to recover 1Merck KGaA would owe a $576.1M break fee to Bio-Techne if the merger ends under certain conditions; Bio-Techne would owe Merck $230.5M per the filing. 2
- Merck KGaA to buy Bio-Techne to boost lab‑tools, cell/gene therapy and precision‑medicine capabilities, aiming for scale as biotech funding slows and R&D spending is expected to recover 1
- Merck KGaA would owe a $576.1M break fee to Bio-Techne if the merger ends under certain conditions; Bio-Techne would owe Merck $230.5M per the filing. 2